The Failure of an Auto-Substitution Protocol of Short-Acting Nebulizers for Long-Acting Inhalers to Reduce Cost of Care in a Quaternary Teaching Hospital.
{"title":"The Failure of an Auto-Substitution Protocol of Short-Acting Nebulizers for Long-Acting Inhalers to Reduce Cost of Care in a Quaternary Teaching Hospital.","authors":"Rina W Lee, Mark W Millard","doi":"10.1089/respcare.12385","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> COPD is a common diagnosis driving in-patient admissions. A major component of in-patient COPD management involves nebulized or inhaled bronchodilators. In many hospitals, the in-patient pharmacy limits medication availability and may auto-substitute short-acting nebulized bronchodilators (SANBs) for long-acting inhalers (LAIs) to cut costs; the effect of such policy change on patient care is unknown. <b>Methods:</b> We performed a retrospective, observational study at a quaternary teaching hospital to analyze respiratory therapy utilization in subjects with COPD on home LAI, who were admitted between December 1, 2022-February 28, 2023. We compared resource utilization between the following groups: SANB only, LAI + as-needed SANB, and LAI + scheduled SANB. <b>Results:</b> We reviewed 302 admissions. There were 97 in SANB group, 99 in LAI + as-needed SANB group, and 106 admissions in LAI + scheduled SANB group. Subjects in LAI + as-needed SANB category utilized significantly fewer treatments overall than SANB or LAI + scheduled SANB groups (1.6/d vs 4.2/d vs 4.5/d, respectively, <i>P</i> < .001) and suffered fewer missed treatments (0.2/d vs 1.7/d vs 1.3/d, respectively, <i>P</i> < .001). There was no significant difference in the length of stay between the 3 groups. Furthermore, overall costs were lowest in LAI + as-needed SANB compared to the SANB and LAI + scheduled SANB groups ($117.62/admission vs $219.71/admission vs $375.35/admission, respectively, <i>P</i> < .001). Within the SANB group, we found that only 36.1% of admissions included orders that complied with the auto-substitution policy. <b>Conclusions:</b> In conclusion, for patients with COPD on home LAI admitted to the hospital, substituting scheduled SANB for LAI resulted in higher costs, more frequent treatment utilization, and more missed doses than the alternative regimens. Moreover, most scheduled SANB orders were not reflective of the actual auto-substitution policy.</p>","PeriodicalId":21125,"journal":{"name":"Respiratory care","volume":" ","pages":"469-476"},"PeriodicalIF":2.1000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/respcare.12385","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Background: COPD is a common diagnosis driving in-patient admissions. A major component of in-patient COPD management involves nebulized or inhaled bronchodilators. In many hospitals, the in-patient pharmacy limits medication availability and may auto-substitute short-acting nebulized bronchodilators (SANBs) for long-acting inhalers (LAIs) to cut costs; the effect of such policy change on patient care is unknown. Methods: We performed a retrospective, observational study at a quaternary teaching hospital to analyze respiratory therapy utilization in subjects with COPD on home LAI, who were admitted between December 1, 2022-February 28, 2023. We compared resource utilization between the following groups: SANB only, LAI + as-needed SANB, and LAI + scheduled SANB. Results: We reviewed 302 admissions. There were 97 in SANB group, 99 in LAI + as-needed SANB group, and 106 admissions in LAI + scheduled SANB group. Subjects in LAI + as-needed SANB category utilized significantly fewer treatments overall than SANB or LAI + scheduled SANB groups (1.6/d vs 4.2/d vs 4.5/d, respectively, P < .001) and suffered fewer missed treatments (0.2/d vs 1.7/d vs 1.3/d, respectively, P < .001). There was no significant difference in the length of stay between the 3 groups. Furthermore, overall costs were lowest in LAI + as-needed SANB compared to the SANB and LAI + scheduled SANB groups ($117.62/admission vs $219.71/admission vs $375.35/admission, respectively, P < .001). Within the SANB group, we found that only 36.1% of admissions included orders that complied with the auto-substitution policy. Conclusions: In conclusion, for patients with COPD on home LAI admitted to the hospital, substituting scheduled SANB for LAI resulted in higher costs, more frequent treatment utilization, and more missed doses than the alternative regimens. Moreover, most scheduled SANB orders were not reflective of the actual auto-substitution policy.
背景:慢性阻塞性肺病是导致住院患者入院的常见诊断。慢性阻塞性肺病住院治疗的一个主要组成部分包括雾化或吸入支气管扩张剂。在许多医院,住院药房限制了药物的可得性,可能会自动用短效雾化支气管扩张剂(sanb)代替长效吸入剂(lai)来降低成本;这种政策变化对病人护理的影响尚不清楚。方法:我们在一家第四教学医院进行了一项回顾性观察性研究,分析了在2022年12月1日至2023年2月28日期间入院的COPD家庭LAI患者呼吸治疗的使用情况。我们比较了以下组之间的资源利用率:仅SANB、LAI +按需SANB和LAI +计划SANB。结果:我们回顾了302例入院病例。SANB组97例,LAI +按需SANB组99例,LAI +计划SANB组106例。LAI +按需SANB组的受试者总体上使用的治疗明显少于SANB组或LAI +计划的SANB组(分别为1.6/d vs 4.2/d vs 4.5/d) P P P结论:总之,对于入院接受家庭LAI治疗的COPD患者,以计划的SANB替代LAI导致更高的成本,更频繁的治疗使用,以及比替代方案更多的漏剂量。此外,大多数计划的SANB订单并不反映实际的自动替换策略。
期刊介绍:
RESPIRATORY CARE is the official monthly science journal of the American Association for Respiratory Care. It is indexed in PubMed and included in ISI''s Web of Science.